Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
10 janv. 2025 07h30 HE
|
Absci Corporation; Owkin
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock...
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
08 janv. 2025 07h00 HE
|
Absci Corporation
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy...
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
06 janv. 2025 08h00 HE
|
Absci Corporation; Invetx
VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Invetx, a pioneer in protein-based therapeutics...
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
02 janv. 2025 08h00 HE
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
12 déc. 2024 08h00 HE
|
Absci Corporation
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia Leading AI platform demonstrated breakthrough in successful...
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
21 nov. 2024 08h00 HE
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
12 nov. 2024 07h30 HE
|
Absci Corporation
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel...
Absci to Host R&D Day on December 12, 2024
07 nov. 2024 08h00 HE
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024...
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
31 oct. 2024 08h00 HE
|
Absci Corporation
VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience...
Absci to Participate in Upcoming Investor Conferences
24 oct. 2024 08h00 HE
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...